Vericel Corp Ord Asset Resilience Ratio
Vericel Corp Ord asset resilience ratio. Vericel Corp Ord (VCEL) has an Asset Resilience Ratio of 7.67% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VCEL defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vericel Corp Ord (1997–2025)
Asset resilience ratio of Vericel Corp Ord from 1997 to 2025. This chart shows how Vericel Corp Ord's Asset Resilience Ratio has changed over time. Read Vericel Corp Ord (VCEL) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vericel Corp Ord's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Vericel Corp Ord (VCEL) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.41 Million | 7.67% |
| Total Liquid Assets | $37.41 Million | 7.67% |
Asset Resilience Insights
- Limited Liquidity: Vericel Corp Ord maintains only 7.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Vericel Corp Ord Industry Peers by Asset Resilience Ratio
Compare Vericel Corp Ord's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Vericel Corp Ord Asset Resilience Ratio by Year (1997–2025)
Vericel Corp Ord asset resilience ratio by year from 1997 to 2025. The table below shows the annual Asset Resilience Ratio data for Vericel Corp Ord.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.67% | $37.41 Million | $487.97 Million | -1.97pp |
| 2024-12-31 | 9.64% | $41.69 Million | $432.72 Million | -1.81pp |
| 2023-12-31 | 11.44% | $40.47 Million | $353.66 Million | -13.64pp |
| 2022-12-31 | 25.08% | $68.47 Million | $273.00 Million | +10.69pp |
| 2021-12-31 | 14.39% | $35.07 Million | $243.71 Million | -6.13pp |
| 2020-12-31 | 20.52% | $42.19 Million | $205.61 Million | -7.43pp |
| 2019-12-31 | 27.95% | $42.83 Million | $153.24 Million | -26.51pp |
| 2018-12-31 | 54.46% | $64.64 Million | $118.69 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $54.58 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $48.60 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $34.31 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $47.58 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $9.21 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $15.18 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $7.74 Million | -- |
| 2010-12-31 | 15.23% | $5.00 Million | $32.83 Million | -10.71pp |
| 2009-12-31 | 25.94% | $5.00 Million | $19.28 Million | +3.17pp |
| 2008-12-31 | 22.77% | $5.97 Million | $26.22 Million | -22.55pp |
| 2007-12-31 | 45.32% | $14.89 Million | $32.85 Million | -30.36pp |
| 2006-12-31 | 75.67% | $33.96 Million | $44.88 Million | +22.55pp |
| 2005-12-31 | 53.12% | $18.01 Million | $33.90 Million | -46.00pp |
| 2004-12-31 | 99.12% | $18.01 Million | $18.17 Million | +90.46pp |
| 2002-12-31 | 8.66% | $1.00 Million | $11.55 Million | +0.26pp |
| 2001-12-31 | 8.40% | $1.00 Million | $11.90 Million | -71.09pp |
| 2000-12-31 | 79.49% | $10.68 Million | $13.44 Million | +5.67pp |
| 1998-12-31 | 73.82% | $9.13 Million | $12.37 Million | -14.70pp |
| 1997-12-31 | 88.52% | $18.51 Million | $20.91 Million | -- |
About Vericel Corp Ord
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more